Edwards Lifesciences Corporation Stock News

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of a solid foundation for innovative therapies.

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.

The stock market, as measured by the S&P 500 Index SPX, -0.64% ), has been moving upward. The U.S. benchmark index is essentially crawling up the higher “modified Bollinger Bands” (mBB), which is

The growing adoption of the PASCAL Precision system in Europe and the United States and Edwards' premium products across all regions have driven Edwards Lifesciences' (EW) Q2 revenues.

Edwards Lifesciences Corporation (NYSE:EW ) Q2 2023 Earnings Conference Call July 26, 2023 5:00 PM ET Company Participants Mark Wilterding - SVP, IR and Treasurer Bernard Zovighian - CEO Scott Ullem -

Edwards Lifesciences Corp on Wednesday slightly raised its annual forecasts for sales and profit, but slower-than-expected revenue growth in the company's artificial heart valves dragged its shares do

Edwards Lifesciences stock fell late Wednesday after the medtech company reported Q2 earnings, narrowly topping profit and revenue expectations.

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Avanos Medical (AVNS) and Edwards Lifesciences (EW). But which of these two stocks offers value inve

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business.

IRVINE, Calif. , July 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2023 after the market closes on Wednesday, July 26

Edwards Lifesciences (EW) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, EW broke through the 20-day moving average, which suggests

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RACE, GWW, ALLE and EW are some stocks that hold promise.

Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.

Edwards Lifesciences is still reporting solid top-line growth in Q1/23 but the bottom line declined and fiscal 2022 also saw low growth rates. Aside from actual growth rates in the last few quarters,

Medical device stocks, including Edwards Lifesciences, have struggled in recent years, with EW's stock wavering amid uncertainty around its Transcatheter Aortic Valve Replacement procedure. Despite so